LaNova Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

LaNova Medicines will present two posters featuring preclinical data of LM-108 and LM-305 (Abstract No. 6008 & 6020) at the American Association for Cancer Research (AACR) 2022 Annual Meeting, to be held April 8-13, 2022.

About LM-108: LM-108 is a monoclonal antibody targeting CCR8 to modulate the tumor microenvironment by specifically removing tumor-infiltrating Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Tregs. LM-108 can potentially bring new treatment options to patients with advanced tumors or resistant to existing cancer immunotherapies. LM-108 is in phase I clinical study now.

About LM-305: LM-305 is the first ADC drug targeting GPRC5D based on a specific monoclonal antibody conjugated with an effective payload. LM-305 can potentially be used for the treatment of hematological malignancies such as multiple myeloma.